Replies to post #27924 on MannKind Corp. (MNKD)

[Hypi]

Yeah it sucks we have to wait until ADA for these results. Just another quarter down the tubes before we get more meaningful and necessary information out to the Endos, GP's and Diabetic community. In the mean time its like watching paint dry as the stock can't get any real movement and I'm sure MNKD is running the ATM. Ugh

[parkourstar]

Seriously? Endos could care less about what form of insulin they use. Likely more important to them are the kickbacks and perks they receive from BPs with money -- things that MNKD is too broke to provide.

What does matter is insurance and they will not be impressed by a four week pilot trial involving patients checking glucose at 1 and 2 hours post-meals and dosing accordingly. Indeed, they might even be put off at the amounts of afrezza required to keep a patient "in range."

No, A1c is what matters to them -- long term control of A1c. Until MNKD provides data showing better long term control of A1c than lispro, it is pretty much guaranteed to remain a dud.

[$Pistol Pete$]

This is a loading zone IMO

Go $MNKD